A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)

Abstract Treatment options for nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D), two conditions which coexist, are limited though weight loss is an important strategy to improve outcomes in either disease. Glucagon-like peptide 1 receptor agonist (GLP1-RA) present a novel option to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Samit Ghosal, Debasis Datta, Binayak Sinha
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/af86958c8fb04d7a8cb85eb155be7f25
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:af86958c8fb04d7a8cb85eb155be7f25
record_format	dspace
spelling	oai:doaj.org-article:af86958c8fb04d7a8cb85eb155be7f252021-11-14T12:23:22ZA meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)10.1038/s41598-021-01663-y2045-2322https://doaj.org/article/af86958c8fb04d7a8cb85eb155be7f252021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01663-yhttps://doaj.org/toc/2045-2322Abstract Treatment options for nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D), two conditions which coexist, are limited though weight loss is an important strategy to improve outcomes in either disease. Glucagon-like peptide 1 receptor agonist (GLP1-RA) present a novel option to treat this dual disease by their salutary effects on glycaemic control and weight reduction. Eight randomized controlled trials on T2D and NAFLD from the Cochrane Library, Embase, and PubMed were included in this meta-analysis. The Comprehensive Meta-Analysis Software version 3 was used to calculate the effect size. In a pooled population of 615 patients—297 on GLP1-RA and 318 in the control arm, GLP1-RA produced a significant improvement in alanine aminotransferase [standardised mean difference (SDM), − 0.56, 95% CI − 0.88 to − 0.25, P < 0.01], aspartate aminotransferase (SDM, − 0.44, SE, 95% CI − 0.64 to − 0.24, P < 0.01), gamma glutaryl transaminase (SDM, − 0.60, 95% CI − 0.86 to − 0.34, P < 0.01) and reduction in liver fat content (LFC) (SDM, − 0.43, 95% CI − 0.74 to − 0.12, P < 0.01), as well as glycosylated haemoglobin (SDM, − 0.40, 95% CI, − 0.61 to − 0.19, P < 0.01) and weight (SDM, − 0.66, 95% CI, − 0.88 to − 0.44, P < 0.01), in comparison to standard of care or placebo. Significant improvement in biopsy resolution was also seen in the GLP1-RA arm (Rate Ratio, 6.60, 95% CI 2.67 to 16.29, P < 0.01). This is possibly the first meta-analysis conducted exclusively in patients with T2D and NAFLD which presents a strong signal that GLP1-RA, improve liver function and histology by improving glycaemia, reducing body weight and hepatic fat, which in turn reduces hepatic inflammation. Trial Registration: PROSPERO (ID: CRD42021228824).Samit GhosalDebasis DattaBinayak SinhaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Samit Ghosal Debasis Datta Binayak Sinha A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
description	Abstract Treatment options for nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D), two conditions which coexist, are limited though weight loss is an important strategy to improve outcomes in either disease. Glucagon-like peptide 1 receptor agonist (GLP1-RA) present a novel option to treat this dual disease by their salutary effects on glycaemic control and weight reduction. Eight randomized controlled trials on T2D and NAFLD from the Cochrane Library, Embase, and PubMed were included in this meta-analysis. The Comprehensive Meta-Analysis Software version 3 was used to calculate the effect size. In a pooled population of 615 patients—297 on GLP1-RA and 318 in the control arm, GLP1-RA produced a significant improvement in alanine aminotransferase [standardised mean difference (SDM), − 0.56, 95% CI − 0.88 to − 0.25, P < 0.01], aspartate aminotransferase (SDM, − 0.44, SE, 95% CI − 0.64 to − 0.24, P < 0.01), gamma glutaryl transaminase (SDM, − 0.60, 95% CI − 0.86 to − 0.34, P < 0.01) and reduction in liver fat content (LFC) (SDM, − 0.43, 95% CI − 0.74 to − 0.12, P < 0.01), as well as glycosylated haemoglobin (SDM, − 0.40, 95% CI, − 0.61 to − 0.19, P < 0.01) and weight (SDM, − 0.66, 95% CI, − 0.88 to − 0.44, P < 0.01), in comparison to standard of care or placebo. Significant improvement in biopsy resolution was also seen in the GLP1-RA arm (Rate Ratio, 6.60, 95% CI 2.67 to 16.29, P < 0.01). This is possibly the first meta-analysis conducted exclusively in patients with T2D and NAFLD which presents a strong signal that GLP1-RA, improve liver function and histology by improving glycaemia, reducing body weight and hepatic fat, which in turn reduces hepatic inflammation. Trial Registration: PROSPERO (ID: CRD42021228824).
format	article
author	Samit Ghosal Debasis Datta Binayak Sinha
author_facet	Samit Ghosal Debasis Datta Binayak Sinha
author_sort	Samit Ghosal
title	A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
title_short	A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
title_full	A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
title_fullStr	A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
title_full_unstemmed	A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
title_sort	meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (glp1-ra) in nonalcoholic fatty liver disease (nafld) with type 2 diabetes (t2d)
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/af86958c8fb04d7a8cb85eb155be7f25
work_keys_str_mv	AT samitghosal ametaanalysisoftheeffectsofglucagonlikepeptide1receptoragonistglp1rainnonalcoholicfattyliverdiseasenafldwithtype2diabetest2d AT debasisdatta ametaanalysisoftheeffectsofglucagonlikepeptide1receptoragonistglp1rainnonalcoholicfattyliverdiseasenafldwithtype2diabetest2d AT binayaksinha ametaanalysisoftheeffectsofglucagonlikepeptide1receptoragonistglp1rainnonalcoholicfattyliverdiseasenafldwithtype2diabetest2d AT samitghosal metaanalysisoftheeffectsofglucagonlikepeptide1receptoragonistglp1rainnonalcoholicfattyliverdiseasenafldwithtype2diabetest2d AT debasisdatta metaanalysisoftheeffectsofglucagonlikepeptide1receptoragonistglp1rainnonalcoholicfattyliverdiseasenafldwithtype2diabetest2d AT binayaksinha metaanalysisoftheeffectsofglucagonlikepeptide1receptoragonistglp1rainnonalcoholicfattyliverdiseasenafldwithtype2diabetest2d
_version_	1718429250713812992

A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)

Ejemplares similares